Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

Detroit, Michigan

Cancer surgery and procedure trials in Detroit, MI

41 cancer surgery and procedure studies are recruiting participants at sites in Detroit as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Detroit at a glance

  • 41 studies are recruiting at a site in Detroit.
  • By phase: Phase 1/2 (1), Phase 2 (12), Phase 3 (24), No phase (2), Observational (2). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (26), government (15).
  • By research area: Lymphoma (15), Breast Cancer (8), Lung Cancer (8), Prostate Cancer (6), Pancreatic Cancer (4).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Detroit

Basic details from each study's public record (the 30 most recently updated of 41). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. The Vanguard Study: Testing a New Way to Screen for Cancer

    • No phase
    • Ages 45 to 75
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Hospital · Henry Ford Medical Center - Detroit Northwest
    Registry record
    NCT06995898 · updated
  2. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Henry Ford Hospital
    Registry record
    NCT07391774 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT06058377 · updated
  4. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital
    Registry record
    NCT05334069 · updated
  5. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Henry Ford Hospital
    Registry record
    NCT06876714 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Lung cancer studies recruiting in Detroit

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital
    Registry record
    NCT06498635 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital
    Registry record
    NCT04267848 · updated
  3. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Henry Ford Health Saint John Hospital
    Registry record
    NCT04181060 · updated
  4. Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital
    Registry record
    NCT03191149 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Detroit

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital
    Registry record
    NCT03866382 · updated
  2. A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.

    • No phase
    • All ages
    • Male participants
    Sponsor
    Henry Ford Health System
    Study site
    Henry Ford Health
    Registry record
    NCT07348367 · updated
  3. Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Henry Ford Hospital
    Registry record
    NCT07200830 · updated
  4. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study site
    Henry Ford Hospital
    Registry record
    NCT05946213 · updated
  5. Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT03678025 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Lymphoma studies recruiting in Detroit

  1. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Henry Ford Health Saint John Hospital
    Registry record
    NCT03739814 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT06337318 · updated
  3. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Children's Hospital of Michigan
    Registry record
    NCT04726241 · updated
  4. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT06724237 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital
    Registry record
    NCT04269902 · updated
  6. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT04840602 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital of Michigan · Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT05675410 · updated
  8. Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Vijendra Singh
    Study site
    Karmanos Cancer Center (Wayne State University)
    Registry record
    NCT05852717 · updated
  9. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT03150693 · updated
  10. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT05976763 · updated
  11. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    • Phase 3
    • Ages 65 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT07321652 · updated
  12. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Michigan
    Registry record
    NCT06124157 · updated
  13. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT05633615 · updated
  14. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    • Phase 3
    • From 365 days, up to 25 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Children's Hospital of Michigan
    Registry record
    NCT03959085 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Detroit, MI on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Detroit

  1. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Henry Ford Health Saint John Hospital
    Registry record
    NCT04858334 · updated
  2. Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

    • Observational
    • Ages 50 to 75
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Henry Ford Health Saint John Hospital
    Registry record
    NCT04239573 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Ask about studies near Detroit

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Michigan

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call